BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center

by Business Wire • 2017/02/06 • 0 Comments

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the acquisition of global rights to ophthalmology-related intellectual property (IP) assets from the University of Pittsburgh’s Medical Center (UPMC), via the school’s Innovation Institute. The technology was developed in part in collaboration with BioTime scientists and includes composition and methodolo

← Carbon Nanotubes as X-ray Contrast Agents to Track Stem Cells Inside Body

Second Sight Medical Products, Inc. Announces Record Date, Subscription Pricing, Expiration Date for Rights Offering and Effectiveness of Its Registration Statement →

Post navigation